HBM Healthcare Investments : announces investment of USD 30 million in Harmony Biosciences

Media Release

Zug, 6 October 2017

Harmony Biosciences, a privately held US-biopharmaceutical company, announced yesterday that it raised USD 270 million from a syndicate of investors. HBM Healthcare Investments participated with USD 30 million in this financing. Dr Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments, will join the Board of Harmony.

Harmony will use the proceeds of this financing to acquire the exclusive right to develop, register and market pitolisant in the United States (US) from French company Bioprojet SCR. Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist which is approved in the European Union (EU) and distributed under the tradename WAKIX® for the treatment of narcolepsy in adult patients with and without cataplexy. Currently, there are no US Food & Drug Administration (FDA) approved H3-receptor antagonist/inverse agonist.

Harmony intends to establish an expanded access program (EAP) for pitolisant in the US in early 2018 and expects to submit a new drug application for the treatment of narcolepsy in adult patients during the first half of 2018.

Narcolepsy is a rare, chronic, debilitating neurological disorder characterized by excessive daytime sleepiness, cataplexy, a sudden loss of muscle control triggered by emotions, and hallucinations among other symptoms. Two types of narcolepsy are currently recognized according to the ICSD3 diagnostic criteria, Type 1 and 2. Type 1 is associated with cataplexy and a reduction in of hypocretin-1 levels, while Type 2 is not associated with cataplexy.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

Harmony is a biopharmaceutical company focused on developing novel treatments for orphan and rare conditions, with an emphasis on CNS disorders. Harmony is focused on providing new treatment options to patients with unmet medical need. Harmony is headquartered in Plymouth Meeting, PA and also has offices in the Chicago, Illinois area. For more information visit: www.harmonybiosciences.com

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (Wertpapierprospektgesetz). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.